A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
NCT02124148
Completed
The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin, cetuximab, pemetrexed, fluorouracil or LY3023414) in participants with advanced cancer or cancer that has spread to another part of the body. The study has multiple parts (A, B, C, D and E). Participants will only enroll in one part.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2020
Locations: Florida Cancer Specialists, Sarasota, Florida +4 locations
Conditions: Neoplasm Metastasis, Colorectal Neoplasms, Breast Cancer
Register for Updates
Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
NCT00721513
Completed
RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. G... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/30/2020
Locations: Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Head and Neck Cancer
Register for Updates
Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies
NCT01110226
Terminated
This is a Phase I Clinical Trial. Phase I studies are designed to determine the amount of investigational drugs that can be safely tolerated and to define the side effects that limit the dose. The drug administered in this study is KML-001. It is a highly soluble, orally available arsenic agent. It is currently being tested to determine its effects on telomerase activity. In other words, the purpose of this research study is to find the highest dose of KML001, that can be given without causing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2020
Locations: University of Maryland Greenebaum Cancer Center, Baltimore, Maryland
Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Platinum Responsive Malignancies
Register for Updates
Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma
NCT00578864
Completed
High-risk neuroblastoma is an aggressive childhood cancer that shows up as a lump or mass in the belly or around the spinal cord in the chest, neck, or pelvis. Often the tumor has spread around the body to the bones or to the soft center of the bone, called the bone marrow. High-risk neuroblastoma often responds to treatment at first, but it frequently comes back and may be even more difficult to treat. Chemotherapy (drug treatments for cancer) is usually given at high doses in short bursts (3... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/13/2020
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Neuroblastoma
Register for Updates
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
NCT02819999
Terminated
The purpose of the study is to test the effect of rovalpituzumab tesirine in the frontline treatment of small cell lung cancer (SCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2020
Locations: University of Colorado, Aurora, Colorado +10 locations
Conditions: Small Cell Lung Cancer
Register for Updates
High-Risk Neuroblastoma Chemotherapy Without G-CSF
NCT02786719
Completed
Patients will be asked to participate in this study because patients have been diagnosed with high-risk neuroblastoma, a common childhood cancer which has aggressive features. If left untreated, high-risk neuroblastoma is fatal. Children with high-risk neuroblastoma often respond to current available treatments, but there is a high risk that the cancer will return. This study will test the safety of giving standard induction treatment for high-risk neuroblastoma without one of the drugs commonl... Read More
Gender:
ALL
Ages:
Between 12 months and 18 years
Trial Updated:
03/05/2020
Locations: Rady Children's Hospital, San Diego, California +1 locations
Conditions: Neuroblastoma
Register for Updates
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)
NCT02357147
Terminated
This study was originally designed as a multicenter, double-blind, randomized, parallel-group study, using a placebo control or amatuximab 5 milligrams per kilogram (mg/kg), administered weekly, designed to evaluate the safety and efficacy of amatuximab in combination with pemetrexed and cisplatin in participants with unresectable Malignant Pleural Mesothelioma (MPM) who have not received prior systemic therapy. Per a business decision made by the Sponsor, participants who were randomized to am... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2020
Locations: Not set, La Jolla, California +48 locations
Conditions: Mesothelioma, Malignant
Register for Updates
Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001
NCT03574818
Terminated
This will be a single-arm study to primarily evaluate the feasibility of administering necitumumab added to gemcitabine and cisplatin as neoadjuvant treatment in treatment-naïve patients with stage IB (tumor size \>4cm), II or IIIA squamous NSCLC. Feasibility will be assessed by the proportion of patients able to proceed to surgery after administering necitumumab in the neoadjuvant setting. These patients would otherwise be offered standard adjuvant chemotherapy (without necitumumab) for squamou... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2020
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Squamous Cell Lung Cancer
Register for Updates
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer
NCT00792701
Completed
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy drugs after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need more treatment until it progresses. In this case, observation may be sufficient. PURPOSE: This phase II trial is studying how well giving gemcitabine together with... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/19/2020
Locations: Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith, Arkansas +146 locations
Conditions: Lung Cancer
Register for Updates
Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)
NCT00522795
Completed
Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001
Gender:
ALL
Ages:
19 years and above
Trial Updated:
02/13/2020
Locations: Lifespan Hospitals, Providence, Rhode Island
Conditions: Esophageal Cancer
Register for Updates
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT00613626
Completed
At this point in the treatment of extensive stage SCLC, we have reached a plateau in survival with conventional chemotherapy and newer regimens are greatly needed. It has been noted that patients with increased VEGF levels have a poorer prognosis. Anti-angiogenic agents hold significant promise in the treatment of patients with extensive stage SCLC. ZD6474, a new inhibitor of the VEGFR-2, has shown favorable action in NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2020
Locations: Helen F. Graham Cancer Center, Newark, Delaware +18 locations
Conditions: Small Cell Lung Cancer
Register for Updates
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
NCT01114958
Completed
This phase I study proposes the use of systemic thiosulfate rescue to allow supradose intra-arterial cisplatin delivery to lung tumors. Eligible patients would be those with at least one lung lesion large enough of characterize angiographically. All patients will first undergo a CT arteriogram of the target tumor. Patients will then receive 2 treatments on 2 consecutive weeks. The primary endpoint will be toxicity, with secondary endpoint of response as measured on week 4. This pilot study will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2020
Locations: University of California, San Diego Moores Cancer Center, La Jolla, California
Conditions: Lung Neoplasms, Neoplasm Metastasis
Register for Updates